English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The pharmacological properties of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one, KP-136 were compared with those of an antiallergic medicament, disodium cromoglycate (DSCG) in experimental asthma models. KP-136 (0.125-1 mg/kg i.v., 0.5-2 mg/kg p.o.) produced a dose-dependent inhibition to allergic asthma of rats and was more potent than DSCG (1-5 mg/kg i.v.). KP-136 (1 mg/kg, i.v.) was also effective on allergic asthma of guinea pigs, although DSCG was ineffective even at a high dose of 50 mg/kg (i.v.). In rats, both KP-136 and DSCG significantly blocked the reduction of histamine content of the trachea after allergic asthma and inhibited the antigen-induced histamine release from lung fragments (KP-136 0.5 micrograms/ml, DSCG 50 micrograms/ml) and peritoneal exudate cells (KP-136 0.1 micrograms/ml, DSCG 10 micrograms/ml). KP-136 also showed relaxation activity for isolated guinea pig trachea at high doses of 2 and 5 micrograms/ml. The major mechanism of the potent antiasthmatic activity of KP-136 is postulated to be the blocking of bronchoactive mediator release. The relaxation of smooth muscle is also suggested to be an additive mechanism.

Effect of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one (KP-136) on experimental asthma: A comparison with disodium cromoglycate.